Key Insights

Highlights

Success Rate

84% trial completion

Published Results

19 trials with published results (20%)

Research Maturity

65 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

12.4%

12 terminated out of 97 trials

Success Rate

84.4%

-2.1% vs benchmark

Late-Stage Pipeline

30%

29 trials in Phase 3/4

Results Transparency

29%

19 of 65 completed with results

Key Signals

19 with results84% success12 terminated

Data Visualizations

Phase Distribution

65Total
Not Applicable (23)
Early P 1 (1)
P 1 (3)
P 2 (9)
P 3 (19)
P 4 (10)

Trial Status

Completed65
Terminated12
Unknown10
Recruiting3
Withdrawn3
Not Yet Recruiting2

Trial Success Rate

84.4%

Benchmark: 86.5%

Based on 65 completed trials

Clinical Trials (97)

Showing 20 of 20 trials
NCT07285785Phase 4Recruiting

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

NCT05471908Not ApplicableRecruiting

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

NCT06331156Phase 3CompletedPrimary

A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants

NCT06579170Active Not RecruitingPrimary

Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada

NCT05972733Phase 2CompletedPrimary

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05281094Phase 2TerminatedPrimary

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT06025695Phase 3CompletedPrimary

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

NCT05870150Not ApplicableActive Not Recruiting

Challenge Non-Typhoidal Salmonella (CHANTS) Study

NCT06007781Phase 1CompletedPrimary

Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants

NCT05836012Phase 2CompletedPrimary

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

NCT05876585Phase 3Not Yet RecruitingPrimary

Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

NCT06524791Not Yet RecruitingPrimary

Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms

NCT02568189Not ApplicableTerminated

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

NCT03046342UnknownPrimary

Gastroenteritis in Pediatric Population of Qatar

NCT04471493Recruiting

Pediatric and Ambulatory Research in Infectious Diseases

NCT02165813Phase 2TerminatedPrimary

Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children

NCT06211621CompletedPrimary

Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic

NCT05805618Early Phase 1UnknownPrimary

Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

NCT01321216CompletedPrimary

Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon

NCT04463082Not ApplicableCompletedPrimary

Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound

Scroll to load more

Research Network

Activity Timeline